Our experienced team of business and medical professionals have a deep understanding of the treatment of psychiatric and brain disorders, as well as experience in creating and scaling new ventures in healthcare, neuroscience, therapeutics and devices, and computer science.
Paul Pyzowski, CEO, is an entrepreneur and executive whose career has spanned healthcare, life sciences, neurotherapeutics, DNA sequencing, and computer science. He founded Altimate Health to apply data science to behavioral health to transform the care of these patients.
Paul was the founding CEO of Aleva Neurotherapeutics, a Swiss-based company that received EU approval for the most advanced deep brain stimulation (DBS) system on the market. He has served as an executive at several MIT spinout companies, including ANDE, which developed the only US government approved field-use product for human DNA identification. He led the sale of Boston Microsystems to Pall Corporation, and the sale of Diagnostic Laboratory Medicine to a national laboratory. He also worked closely with the founders of Neuroelectrics, guiding their therapy for pediatric epilepsy through a successful FDA clinical study.
Paul also has experience in the US healthcare provider market, having managed a hundred-person clinical laboratory assisting physicians treating pain and addiction. He started his career in computational physics as a VP and executive officer at Ansoft (NASDAQ: ANST). He has a BSEE from Carnegie-Mellon, and an MBA from IMD in Lausanne.
Dr. Wasim Q. Malik, PhD, Director, is the Managing Partner at Iaso Ventures. He previously served as Chief Digital Strategist at Roivant Sciences, where he built the digital health strategy and investments business to help accelerate drug development and commercialization across 15+ therapeutic areas. Wasim has served on the faculty at Harvard Medical School and Massachusetts General Hospital, where he built a research program on tech-enabled clinical research in neurology.
Wasim currently serves on the board of directors at Saphetor and Altimate Health, on the business advisory board of the Epilepsy Foundation, as a Senior Advisor at Health Catalyst, and on several startup advisory boards. He has published over 100 research papers and patents. He received his Doctor of Philosophy in electrical engineering from Oxford, postdoctoral training in neuroscience from MIT, and executive education in venture capital and private equity from Harvard Business School.
Maurizio Fava, MD, Scientific Advisor, is Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), director, Division of Clinical Research of the MGH Research Institute, and executive director of the Clinical Trials Network and Institute, (MGH), and associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.
Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 800 original articles published in medical journals with international circulation, articles which have been cited more than 75,000 times in the literature and with an h index of over 135.
Dr. Fava founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry. Under Dr. Fava’s direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work.
Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university.
A. Eden Evins, MD MPH, Scientific Advisor, is Dr. Evins is The Cox Family Professor of Psychiatry in the field of Addiction Medicine, Harvard Medical School and the founder and Director of the Center For Addiction Medicine at MGH.
Dr. Evins has nearly two decades of experience studying the efficacy of pharmacotherapeutic cessation aids in smokers including those with serious mental illness, and on the effect of nicotine on cognitive performance in those with and without schizophrenia.. She has conducted a series of studies that have changed clinical practice guidelines for smoking cessation for those with serious mental illness. Cochrane Reviews on smoking cessation in schizophrenia are based largely on this work. Dr. Evins has extensive ties with Community Health Centers that have made it possible to conduct large clinical studies.
Dr. Evins completed her residency in adult psychiatry at the Massachusetts Mental Health Center and Longwood Psychiatry Residency Training Program. In addition, she completed a fellowship in molecular biology at the Mailman Research Center of McLean Hospital, a fellowship in clinical research at the Massachusetts General Hospital, and a Masters in Public Health with a concentration in Clinical Effectiveness at the Harvard School of Public Health.
Linda Stalters, MSN, Advisor, was the founder and former CEO and Executive Director of the Schizophrenia and Psychosis Action Network (formerly SARDAA), the largest advocacy organization for patients with schizophrenia. In her fifteen years with the organization she was a tireless advocate for patients and their families with pharmaceutical companies, healthcare organizations, and clinicians worldwide.